91 filings
Page 2 of 5
6-K
uem827651zv6pcw
30 Aug 22
Current report (foreign)
8:56am
6-K
d4y0f7snuke
16 Aug 22
Current report (foreign)
4:02pm
6-K
ge7t0m ccstzybgb1
27 May 22
I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab
6:02am
6-K
gi27v9f5
18 May 22
Current report (foreign)
6:34am
6-K
7pbzd
5 May 22
I-Mab Provides Updates on Status under Holding Foreign Companies Accountable Act
12:00am
6-K/A
jf2 bw78kynda6dt
28 Apr 22
Financial results demonstrate strong fundamentals
4:53pm
6-K
ydpe8tt05e3p7k4lsmg
28 Apr 22
I-Mab Announces Appointments of Richard Yeh as Chief Operating Officer and John Hayslip as Chief Medical Officer
9:26am
6-K
9a7fjubq
31 Mar 22
I-Mab Announces Voluntary Lock-ups by Key Shareholders and Senior Management for Long-Term Commitment
4:46pm
6-K/A
8pcreo21odv5n6o
31 Mar 22
Financial results demonstrate strong fundamentals
4:45pm
6-K
kmaxqn06qxe ivz8pf
29 Mar 22
Financial results demonstrate strong fundamentals
9:26am
6-K
k6xwmzk08e
4 Mar 22
I-Mab Receives FDA Orphan Drug Designation for its Novel Claudin 18.2 x 4-1BB Bispecific
6:11am
6-K
tvw58h4f550w47ktt
22 Feb 22
Current report (foreign)
4:04pm
6-K
wrmo02
28 Jan 22
I-Mab’s Announcement on Unusual Price Movement
7:23am
6-K
v32tx4jvp5
21 Dec 21
I-Mab Strengthens Management Team Designed to Accelerate Global Pipeline Development and Transformation Towards Commercialization
6:05am
6-K
2ofp4t
15 Dec 21
I-Mab Presents Interim Clinical Data of Lemzoparlimab in Combination with Rituximab in Relapsed and Refractory Non-Hodgkin Lymphoma at ASH 2021
6:03am
6-K
xgw2x16bk901r6o614d
10 Dec 21
Current report (foreign)
4:02pm
6-K
ezprk5dx e0
8 Dec 21
I-Mab to Pursue Dual Listing Plan on The Main Board of The Stock Exchange of Hong Kong Limited
6:08am
6-K
y5ihn4tv8 ashhw
6 Dec 21
Current report (foreign)
6:06am
6-K
jqwrq6r5s gjoz
12 Nov 21
Index to Consolidated Financial Statements
4:02pm
6-K
zb9jk fgm
12 Nov 21
I-Mab and ABL Bio Report Preclinical Data of 4-1BB-targeting Bispecific Antibodies at 2021 SITC
6:15am